Program Profile

VA-Based Peritoneal Dialysis Program Feasibility Considerations and Process Outline

Author and Disclosure Information

Background: Home dialysis utilization is lower among veterans than in the general US population. Several sociodemographic factors and comorbidities contribute to peritoneal dialysis (PD) underutilization. In 2019, the Veterans Health Administration (VHA) Kidney Disease Program Office convened a PD workgroup to address this concern.

Observations: The PD workgroup was explicitly concerned by the limited availability of PD within the VHA, which frequently requires veterans to transition kidney disease care from US Department of Veterans Affairs medical centers (VAMCs) to non-VHA facilities when they progress from chronic kidney disease to end-stage kidney disease, causing fragmentation of care. Since the administrative requirements and infrastructure of VAMCs vary, the workgroup focused its deliberations on synthesizing a standard process for evaluating the feasibility and establishing a new PD program within any individual VAMC. A 3-phased approach was envisioned, beginning with ascertainment of prerequisites, leading to an examination of the clinical and financial feasibility through the process of data gathering and synthesis, culminating in a business plan that translates the previous 2 steps into an administrative document necessary for obtaining VHA approvals.

Conclusions: VAMCs can use the guide presented here to improve therapeutic options for veterans with kidney failure by establishing a new or restructured PD program.


 

References

Compared with hemodialysis (HD), peritoneal dialysis (PD) offers comparable survival and superior patient-centered and health services outcomes.1,2 This has prompted repeated calls over the past 2 decades for policies to increase the use of home dialysis and, more specifically, for PD in the United States.3,4

Veterans comprise nearly 10% of the population with end-stage kidney disease (ESKD) burden; > 50,000 US veterans are currently on dialysis.5,6 A majority of these veterans receive their chronic kidney disease (CKD) care through their affiliated US Department of Veterans Affairs (VA) medical centers (VAMCs).

figure 1
However, there are only 71 hospital-affiliated or free-standing HD and 28 outpatient PD units within the Veterans Health Administration (VHA) (Figure 1). Together, these units serve only about 3500 veterans on HD and about 300 veterans with PD. More than 90% of veterans receive their dialysis care from non-VA facilities. Thus, veterans progressing from CKD to ESKD commonly need to transition their VA-based nephrology care to non-VA facilities, causing fragmentation of care during a medically fragile period. Such transitions adversely impact the quality of ESKD care and reduce the probability of PD use. PD use among veterans is lower (~7%) compared with the general ESKD population (~12%).7

To address these needs, the VHA National Kidney Disease Program (NKDP) formed a 4-member PD workgroup in 2019. Considering the breadth of challenges involved, the PD workgroup broadly designed its approach based on the I CARE (Integrity, Commitment, Advocacy, Respect, and Excellence) VA Core Values.

figure 2
The workgroup devised a conceptual model with 3 focus areas, each comprising a subgroup led by a workgroup member: respecting the veteran’s choice for PD, advocating for universal access to PD, and providing excellence in PD care within the VHA (Figure 2). While the passage of the Choice Act (2014) and the Mission Act (2018) was recognized to have increased access to PD for veterans through non-VA purchased care, lack of availability within the VA infrastructure was considered a significant residual limitation to greater PD use.8

This review focuses on the initial deliberations of the PD access subgroup and provides a guide to establishing a new local VA PD program.

figure 3
We describe the process by dividing it into 3 operational phases: examining the prerequisites, analyzing clinical and financial feasibility, and outlining the process of administrative approval (Figure 3).

Pages

Recommended Reading

‘Too good to be true’? Ultrasound safely treats kidney stones
Federal Practitioner
Islet transplants in type 1 diabetes durable up to 8 years
Federal Practitioner
Study sheds new light on RAS inhibitors’ role for advanced CKD
Federal Practitioner
Promising new antibiotic emerges for treating UTIs
Federal Practitioner
Dialysis not always best option in advanced kidney disease
Federal Practitioner
Dapagliflozin reduces hospitalizations in patients with CKD
Federal Practitioner
Experts share real-world experience prescribing voclosporin, belimumab for lupus nephritis
Federal Practitioner
Can SGLT2 inhibitors limit acute kidney injury in type 2 diabetes?
Federal Practitioner
Experts share early details prescribing avacopan for ANCA-associated vasculitis
Federal Practitioner
SGLT2 inhibitors: Real-world data show benefits outweigh risks
Federal Practitioner